Covance has extensive experience in cardiovascular, metabolic, endocrine, and renal clinical trials, having completed over 462 studies in these areas. The document provides details on the number of protocols, sites, and patients for the top clinical indications, which include arrhythmias, thrombosis, coronary artery disease, heart failure, hypertension, and others. It also specifies the number of phase I, II, III, and IV studies conducted along with clinical pharmacology projects. Covance has run trials across 64 countries at over 20,000 sites, involving nearly 250,000 patients total.

1. COVANCE CARDIOVASCULAR /
METABOLISM / ENDOCRINE /
RENAL (CVMER) EXPERIENCE
CVMER 462 TOTAL STUDIES
TOP CLINICAL INDICATIONS:
ARRHYTHMIAS
7 Protocols
1,388 Sites
15,092 Patients
THROMBOSIS
5 Protocols
427 Sites
8,904 Patients
CORONARY ARTERY
DISEASE
17 Protocols
1,382 Sites
11,322 Patients
HEART FAILURE
12 Protocols
1,574 Sites
7,888 Patients
SYSTEMIC
HYPERTENSION
16 Protocols
964 Sites
6,111 Patients
REGENERATIVE MEDICINE
4 Protocols
94 Sites
388 Patients
PULMONARY ARTERIAL
HYPERTENSION
11 Protocols
512 Sites
1,268 Patients
PERIPHERAL ARTERY
& VENOUS DISEASES
6 Protocols
1,498 Sites
22,013 Patients
PHASE I
71
Studies
PHASE III
110
Studies
PHASE IV
31
Studies
75
Clin Pharm
175
Studies
LIPIDS DISORDER
24 Protocols
3,890 Sites
45,234 Patients
CVOT
16
Studies
CONGENITAL
HEART DISEASE
3 Protocols
33 Sites
184 Patients
PHASE II

2. 64 COUNTRIES 20,493 SITES 246,938 PATIENTS
Covance helped bring
Source: Internal metrics 2012-2016
Total number includes additional unclassified studies
Covance Inc., headquartered in Princeton, NJ, USA is the drug development
business of Laboratory Corporation of America Holdings (LabCorp).
COVANCE is a registered trademark and the marketing name for Covance
Inc. and its subsidiaries around the world.
The Americas + 1.888.COVANCE
(+1.888.268.2623) + 1.609.452.4440
Europe / Africa + 00.800.2682.2682 +44.1423.500888
Asia Pacific + 800.6568.3000 +65.6.5686588
© Copyright 2018 Covance Inc.
INFCDS008-0118
CKD
21 Protocols
659 Sites
9,892 Patients
DIABETES TYPE II
78 Protocols
3,491 Sites
23,354 Patients
ENDOCRINE
DISORDERS
10 Protocols
786 Sites
46,406 Patients
HEPATIC
IMPAIRMENT
67 Protocols
245 Sites
2,324 Patients
ENDOCRINOLOGY
2 Protocols
401 Sites
5,383 Patients
NEPHROLOGY
10 Protocols
1,073 Sites
15,015 Patients
RENAL IMPAIRMENT
47 Protocols
903 Sites
14,599 Patients
NASH
6 Protocols
709 Sites
4,405 Patients
TOP CLINICAL INDICATIONS
CONTINUED:
DIABETES TYPE I
15 Protocols
467 Sites
3,882 Patients
ENDOCRINE RARE
DISEASES
27 Protocols
437 Sites
5,078 Patients
49 of the top 50
best selling drugs to patients worldwide